Aradigm is an emerging specialty pharmaceutical company engaged in developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases. The company’s product candidates address the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia, anthrax … Continue reading →

Aastrom Biosciences is the leading developer of patient-specific, expanded multicellular therapies for treating severe, chronic cardiovascular diseases. The company’s proprietary cell-processing technology enables the manufacturing of ixmyelocel-T, which is a patent-specific multicellular therapy expanded from a patient’s own bone marrow … Continue reading →

DARA BioSciences is a specialty pharmaceutical company engaged in developing and commercializing oncology treatment and supportive care products. Through agreements with various entities, the company has comprehensive commercial coverage across the national oncology market. DARA is part of an integrated … Continue reading →

BioLineRx is a biopharmaceutical development company focused on building a portfolio of products to address unmet medical needs or offer advantages over currently available therapies. The company’s portfolio presently consists of six clinical stage candidates, in addition to products in … Continue reading →

SciClone Pharmaceuticals is a specialty pharmaceutical company with its primary focus in China. The company’s product portfolio includes therapies for oncology, infectious diseases and disorders of the cardiovascular, urological, respiratory and central nervous systems. Headquartered in Foster City, Calif., SciClone … Continue reading →

Orexigen Therapeutics, a biopharmaceutical company, is focused on treating obesity. Contrave, Orexigen’s lead product candidate, has completed Phase III clinical trials, and a New Drug Application has been submitted and reviewed by the U.S. Food and Drug Administration. The company … Continue reading →

Immunovaccine is a clinical-stage vaccine development company focused on the advancement of its patented DepoVax vaccine adjuvanting platform and product candidates for cancer therapy, infectious disease and animal health. Demonstrating safety and immunogenicity potential, Immunovaccine has advanced its platform technology … Continue reading →

iCo Therapeutics is a re-profiling company engaged in re-dosing or reformulating drugs with clinical history for new or expanded indications. The company owns the global rights to three products: iCo-007, currently in a Phase I trial in diabetic macular edema … Continue reading →

BioDelivery Sciences International is a specialty pharmaceutical company leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize new applications of proven therapeutics – either independently or in partnerships with third parties. The company is currently focused … Continue reading →

Oragenics is dedicated to becoming a global leader in probiotics for oral health in humans and pets and in novel antibiotics against infectious disease. The company is engaged in developing, marketing and selling proprietary probiotics under the brand names Evora … Continue reading →